Is preclinical data sharing the new norm?
Related Experiment Video
Updated: Mar 21, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
1Lhasa Limited, Granary Wharf House, 2 Canal Wharf, Leeds LS11 5PS, UK.
Abstract:
Is preclinical data sharing the new norm? In my experience, it is certainly becoming more commonplace. However, it is not yet standard practice and remains the preserve of special projects. Here, I expound the benefits of sharing proprietary preclinical data using examples of successful initiatives. The main barriers to data sharing are then described, with suggestions for how these might be overcome. To maximise the benefits and minimise the risks involved, I suggest that organisations look to develop standard operating procedures for data sharing.
Related Concept Videos
Preclinical Development: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinically Relevant Drug Product Specifications: Methods of Establishment
Bioequivalence studies: Biowaivers
Bioavailability Study Design: Healthy Subjects Versus Patients

